Novartis Pharmaceuticals Canada Inc. is pleased to announce the successful conclusion of negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for the public reimbursement of Leqvio® ...

Company N.V. announced that the European Medicines Agency, EMA, has validated the Marketing Authorization Application, ...

Filings both for the obicetrapib monotherapy and obicetrapib plus ezetimibe fixed-dose combination submitted to EMA by our partner, Menarini, for treatment of adults with primary hypercholesterolemia ...

The experimental cholesterol drug obicetrapib slowed Alzheimer’s biomarkers, over 12 months in patients with cardiovascular ...

Learn more about paternal zygosity testing, which can help reveal if there is a risk of a fetus developing HDFN.

Lung clearance index, lung function and respiratory symptoms improved in children aged 6 to 11 years with cystic fibrosis ...

Objective Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency is an inherited adrenal steroid synthesis disorder included in Dutch newborn screening (NBS) since 2002. Screening ...

If you have two copies of the same version of a gene, you are homozygous for that gene. If you have two different versions of a gene, you are heterozygous for that gene.

Learn about the causes, symptoms, and treatment of heterozygous familial hypercholesterolemia, a disease that causes you to have very high cholesterol levels.

Objectives Heterozygous familial hypercholesterolaemia (FH) confers a significant risk for premature cardiovascular disease (CVD). However, the estimated prevalence of FH varies substantially among ...

Heterozygous FMF can be monitored using S100A8/A9 and S100A12 levels, with colchicine discontinuation possible among patients with this genotype.